<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[david phillips Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/david+phillips.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to david phillips]]></description>
	<s:counts start="0" returned="20" found="308" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Walmart Looks to Leave GameStop '4 Dead' This Christmas]]></title>
		<link><![CDATA[http://industry.bnet.com/retail/10005561/wal-mart-looks-to-leave-gamestop-4-dead-this-christmas/]]></link>
		<description><![CDATA[GameStop could find coal in its Christmas stocking this year, as Wal-Mart announced price rollbacks on top video game titles good through December 24. The box retailer's move could cut into holiday season sales at the nation's largest video game retailer. by David Phillips]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 07 Dec 2009 12:52:44 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/wal-mart+stores+inc..html"><![CDATA[Wal-Mart Stores Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/retail+company.html"><![CDATA[Retail Company]]></category>
		<category domain="http://resources.bnet.com/topic/video+game.html"><![CDATA[Video Game]]></category>
		<category domain="http://resources.bnet.com/topic/video.html"><![CDATA[Video]]></category>
		<category domain="http://resources.bnet.com/topic/games.html"><![CDATA[Games]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+communications.html"><![CDATA[Corporate Communications]]></category>
		<category domain="http://resources.bnet.com/topic/personal+technology.html"><![CDATA[Personal Technology]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WMT</category>
		<category domain="tickers">WMT</category>
	</item>
	<item>
		<title><![CDATA[Valero Energy Sours on Heavy Crude, Sweet on Ethanol]]></title>
		<link><![CDATA[http://industry.bnet.com/energy/10002600/valero-energy-sours-on-heavy-crude-sweet-on-ethanol/]]></link>
		<description><![CDATA[Valero Energy announced the permanent closing of its Delaware City refinery last month, prompted by financial losses and annual cost savings of $450 million expected from the shutdown. Though refinery operations are struggling with soured demand for petroleum products, including gasoline, its nascent ethanol business looks sweet. Is there a...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 04 Dec 2009 15:38:18 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/petroleum.html"><![CDATA[Petroleum]]></category>
		<category domain="http://resources.bnet.com/topic/valero+l.p..html"><![CDATA[Valero L.P.]]></category>
		<category domain="http://resources.bnet.com/topic/telecom+%2526+utilities.html"><![CDATA[Telecom & Utilities]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
	</item>
	<item>
		<title><![CDATA[Can Novartis Win Race to Launch First Oral Drug for MS?]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005592/can-novartis-win-race-to-launch-first-ms-oral-drug/]]></link>
		<description><![CDATA[Novartis AG is jockeying with German drug maker Merck KgaA to deliver the first disease-modifying treatment for relapsing forms of multiple sclerosis that can be taken orally, rather than by infusion or injection. Fingolimod could finally move ahead in the race to market, as the FDA rejected Merck's new drug...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 03 Dec 2009 10:25:11 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://resources.bnet.com/topic/microsoft+corp..html"><![CDATA[Microsoft Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/tablets.html"><![CDATA[Tablets]]></category>
		<category domain="http://resources.bnet.com/topic/notebooks.html"><![CDATA[Notebooks]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/hardware.html"><![CDATA[Hardware]]></category>
		<category domain="http://resources.bnet.com/topic/notebooks+%2526+tablets.html"><![CDATA[Notebooks & Tablets]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MSFT</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">MRK,MSFT,NVS</category>
	</item>
	<item>
		<title><![CDATA[FDA Offers Pfizer's HIV Drug Selzentry New Life -- For All the Good It Will Do]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005550/fda-offers-pfizers-hiv-drug-selzentry-new-life-for-all-the-good-it-will-do/]]></link>
		<description><![CDATA[The FDA approved Pfizer's anti-HIV drug Selzentry for expanded use in combination with other antiretroviral agents for treatment-naÃ¯ve patients who are infected with only CCR5-tropic HIV-1. Contrary to company expectations, perceived limitations of this entry inhibitor could stall efforts to facilitate usage beyond salvage therapy. by David Phillips]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 30 Nov 2009 10:57:52 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/hiv+virus.html"><![CDATA[HIV Virus]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Can Novartis JAK Up Incyte's Profitability?]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005537/can-novartis-jak-up-incytes-profitability/]]></link>
		<description><![CDATA[Paul Friedman, chief executive of Incyte, believes that a newly-inked collaborative and licensing deal with Novartis for INCB18424, an oral JAK1/JAK2 inhibitor entering late-stage development for the blood disorder myelofibrosis, could drive the company to first-time profitability. Although early clinical evidence suggests that regulating cell signaling through this cytokine pathway...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 30 Nov 2009 10:52:09 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">NVS</category>
	</item>
	<item>
		<title><![CDATA[Inconvenient Truth: Recovery But No Recovery at Driller Patterson-UTI]]></title>
		<link><![CDATA[http://industry.bnet.com/energy/10002556/inconvenient-truth-recovery-but-no-recovery-at-driller-patterson-uti/]]></link>
		<description><![CDATA[Patterson-UTI Energy had an average of 88 drilling rigs operating in October, up from an average count of 73 in the third-quarter ended September. Talk of a significant recovery in demand might be premature, however, given the current supply overhang in the natural gas market.    With about...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 25 Nov 2009 11:30:11 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/recovery.html"><![CDATA[Recovery]]></category>
		<category domain="http://resources.bnet.com/topic/inconvenient+truth.html"><![CDATA[Inconvenient Truth]]></category>
		<category domain="http://resources.bnet.com/topic/rig.html"><![CDATA[Rig]]></category>
		<category domain="http://resources.bnet.com/topic/natural+gas.html"><![CDATA[Natural Gas]]></category>
		<category domain="http://resources.bnet.com/topic/patterson-uti+energy.html"><![CDATA[Patterson-UTI Energy]]></category>
		<category domain="http://resources.bnet.com/topic/competitor+helmerich+%2526+payne.html"><![CDATA[Competitor Helmerich & Payne]]></category>
		<category domain="http://resources.bnet.com/topic/telecom+%2526+utilities.html"><![CDATA[Telecom & Utilities]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
	</item>
	<item>
		<title><![CDATA[Novartis Looks at Combination Pills to Fix Hypertension Franchise]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005479/novartis-looks-to-combination-pills-to-fix-hypertension-franchise/]]></link>
		<description><![CDATA[Novartis could find its leadership position in blood pressure therapies challenged in the next two years, owing to generic intrusion on its flagship anti-hypertensive drug Diovan. Near-term, with no novel agents emerging from its  drug pipeline, the drugmaker is reaching into its life cycle management playbook and introducing a...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 24 Nov 2009 10:44:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://resources.bnet.com/topic/leadership.html"><![CDATA[Leadership]]></category>
		<category domain="http://resources.bnet.com/topic/management.html"><![CDATA[Management]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">NVS</category>
	</item>
	<item>
		<title><![CDATA[Why J&J's Stelara Launch Should Target Dermatologists First]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005423/why-jjs-stelara-launch-should-target-dermatologists-first/]]></link>
		<description><![CDATA[Johnson & Johnson recently launched Stelara for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis. Although Stelara is entering a crowded treatment room for psoriasis, this first-in-class interleukin IL inhibitor could still put the "no more tears" back in J&J's future -- if...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 20 Nov 2009 11:48:31 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="tickers">JNJ</category>
	</item>
	<item>
		<title><![CDATA[FDA Delays Genzyme's Lumizyme, Manufacturing Problems Blamed]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005372/a-cure-for-genzymes-pompe-disease-treatment-ceo-termeers-ouster/]]></link>
		<description><![CDATA[Genzyme announced that the FDA is delaying final approval of the company's application to market Lumizyme alglucosidase alfa for the treatment of Pompe disease. Not unexpected, given FDA regulators had sent out a memo last Friday warning healthcare providers that enzyme replacement drugs made at the Allston Landing plant might...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 19 Nov 2009 07:56:16 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/genzyme+corp..html"><![CDATA[Genzyme Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/manufacturing.html"><![CDATA[Manufacturing]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GENZ</category>
		<category domain="tickers">GENZ</category>
	</item>
	<item>
		<title><![CDATA[Lessons Not Learned at ITT Educational Services]]></title>
		<link><![CDATA[http://industry.bnet.com/technology/10004107/lessons-not-learned-at-itt-educational-services/]]></link>
		<description><![CDATA[ITT Educational Services reported that new student enrollment increased 27.2 percent to 27,738 in its third quarter. With private sector lending still in decline, the for-profit educator is increasingly funding growth through an internal loan program. Despite more lending to sub-prime enrollees, few industry watchers seem concerned that the emperor...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 18 Nov 2009 10:13:38 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/student.html"><![CDATA[Student]]></category>
		<category domain="http://resources.bnet.com/topic/loan+program.html"><![CDATA[Loan Program]]></category>
		<category domain="http://resources.bnet.com/topic/balance+sheets.html"><![CDATA[Balance Sheets]]></category>
		<category domain="http://resources.bnet.com/topic/revenue+recognition.html"><![CDATA[Revenue Recognition]]></category>
		<category domain="http://resources.bnet.com/topic/operational+accounting.html"><![CDATA[Operational Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/financial+services.html"><![CDATA[Financial Services]]></category>
		<category domain="http://resources.bnet.com/topic/financial+statements.html"><![CDATA[Financial Statements]]></category>
		<category domain="http://resources.bnet.com/topic/financial+accounting.html"><![CDATA[Financial Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
	</item>
	<item>
		<title><![CDATA[Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005261/fda-looking-to-regulate-biogens-invisible-salesforce/]]></link>
		<description><![CDATA[On November 2, Biogen Idec updated the prescribing label for its blockbuster multiple sclerosis drug Tysabri natalizumab after consultation with the FDA. Aside from acknowledging that the risk of developing progressive multifocal leukoencephalopathy PML, an often fatal brain infection, increases with longer duration of treatment, no other revisions concerning the...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 12 Nov 2009 12:19:16 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/risk.html"><![CDATA[Risk]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/social+media.html"><![CDATA[Social Media]]></category>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/security.html"><![CDATA[Security]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/management.html"><![CDATA[Management]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="tickers">BIIB</category>
	</item>
	<item>
		<title><![CDATA[Band-Aid Won't Stop Generic Bleeding at Johnson & Johnson]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005232/band-aid-wont-stop-generic-bleeding-at-johnson-johnson/]]></link>
		<description><![CDATA[Despite best efforts to build a diversified health care business, the fortunes of Johnson & Johnson remain tethered to prescription drug sales, which comprise almost 40 percent of total revenue. Generic cannibalization of blockbuster drugs that have lost -- or are losing -- patent protection, combined with other challenges irrupting...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 11 Nov 2009 14:11:32 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/revenue.html"><![CDATA[Revenue]]></category>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://resources.bnet.com/topic/health+care.html"><![CDATA[Health Care]]></category>
		<category domain="http://resources.bnet.com/topic/vertical+industries.html"><![CDATA[Vertical Industries]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="tickers">JNJ</category>
	</item>
	<item>
		<title><![CDATA[MannKind's CFO Pfeffer Upbeat on Afresa's Future]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005189/mannkind-cfo-pfeffer-upbeat-on-afresas-future/]]></link>
		<description><![CDATA[MannKind Corp.â€˜s announcement last month that no partnership deal was in the offing for its inhaled-insulin product Afresa this year has lead to widespread commentary about the actual clinical and commercial viability of this investigational prandial drug therapy for diabetes care. In a phone call with me on Wednesday, chief...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 10 Nov 2009 06:54:36 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/mannkind+corp..html"><![CDATA[MannKind Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/partnership.html"><![CDATA[Partnership]]></category>
		<category domain="http://resources.bnet.com/topic/cfo.html"><![CDATA[CFO]]></category>
		<category domain="http://resources.bnet.com/topic/mannkind.html"><![CDATA[MannKind]]></category>
		<category domain="http://resources.bnet.com/topic/business+structures.html"><![CDATA[Business Structures]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MNKD</category>
		<category domain="tickers">MNKD</category>
	</item>
	<item>
		<title><![CDATA[Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005164/teva-in-turnabout-sues-to-protect-its-multiple-sclerosis-drug-copaxone/]]></link>
		<description><![CDATA[Is this a rare case of Teva Pharmaceutical being forced to swallow its own bitter medicine? The world's largest generic manufacturer, with a core value founded on its unflinching willingness to challenge the patented protection of branded products owned by other drugmakers, is suing generic rival Mylan. Teva alleges patent...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 06 Nov 2009 13:45:33 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/teva.html"><![CDATA[Teva]]></category>
		<category domain="http://resources.bnet.com/topic/intellectual+property.html"><![CDATA[Intellectual Property]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
	</item>
	<item>
		<title><![CDATA[BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005074/biocryst-pharmaceuticals-antiviral-peramivir-aims-to-keep-influenza-body-count-low/]]></link>
		<description><![CDATA[BioCryst Pharmaceuticals' experimental drug peramivir is now available for treatment of hospitalized patients with suspected or confirmed 2009 H1N1 influenza under emergency use authorization EUA by the FDA. The resultant recommendation, however, may have sprung from the need for political expediency to showcase that swine flu will not become President...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 02 Nov 2009 13:47:40 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/h1n1+flu.html"><![CDATA[H1N1 Flu]]></category>
		<category domain="http://resources.bnet.com/topic/biocryst.html"><![CDATA[BioCryst]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
	</item>
	<item>
		<title><![CDATA[More Tysabri Problems; Time for a Biogen-Idec Credibility Check]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005050/moretysabri-problemstime-for-biogen-idec-credibility-check/]]></link>
		<description><![CDATA[Unsubstantiated whisperings about Biogen Idec and its controversial multiple sclerosis drug took an ugly turn to the truth on Thursday  when European regulators disclosed case number 24 of progressive multifocal leukoencephalopathy, a serious brain infection known as PML, in a relapsed MS patient receiving Tysabri natalizumab infusions. With 11...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 30 Oct 2009 12:59:04 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/regulations.html"><![CDATA[Regulations]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="tickers">BIIB</category>
	</item>
	<item>
		<title><![CDATA[Continental Airlines Grounds Puppy from Flight, Hikes Fees On Humans]]></title>
		<link><![CDATA[http://industry.bnet.com/travel/10003922/continental-airlines-grounds-puppy-from-flight/]]></link>
		<description><![CDATA[Recent service fee and domestic fare increases by Continental Airlines suggest the worldâ€™s fifth largest airline believes that pricing power has shifted from the consumer back to air carriers like itself. This growing confidence was all the more on display when the air carrier â€" damn the bad PR â€"...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 29 Oct 2009 12:16:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/continental+airlines+inc..html"><![CDATA[Continental Airlines Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/public+relations.html"><![CDATA[Public Relations]]></category>
		<category domain="http://resources.bnet.com/topic/pricing.html"><![CDATA[Pricing]]></category>
		<category domain="http://resources.bnet.com/topic/marketing+research.html"><![CDATA[Marketing Research]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+communications.html"><![CDATA[Corporate Communications]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CAL</category>
		<category domain="tickers">CAL</category>
	</item>
	<item>
		<title><![CDATA[Streaming Profits for Netflix from Sony PlayStation 3 Deal]]></title>
		<link><![CDATA[http://industry.bnet.com/technology/10003906/streaming-profits-for-netflix-from-sony-playstation-3-deal/]]></link>
		<description><![CDATA[Netflix will make its video streaming service available to Sony PlayStation 3 owners next month. Given its existing Internet distribution deals for a variety of other devices, this latest arrangement should help the company lower operating costs and overall churn rates in coming quarters. by David Phillips]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 29 Oct 2009 09:59:18 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/netflix+inc..html"><![CDATA[NetFlix Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/sony+corp..html"><![CDATA[Sony Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/sony+playstation+3.html"><![CDATA[Sony PlayStation 3]]></category>
		<category domain="http://resources.bnet.com/topic/streaming+video.html"><![CDATA[Streaming Video]]></category>
		<category domain="http://resources.bnet.com/topic/sony+playstation.html"><![CDATA[Sony Playstation]]></category>
		<category domain="http://resources.bnet.com/topic/web+site+development.html"><![CDATA[Web Site Development]]></category>
		<category domain="http://resources.bnet.com/topic/game+players.html"><![CDATA[Game Players]]></category>
		<category domain="http://resources.bnet.com/topic/web+technology.html"><![CDATA[Web Technology]]></category>
		<category domain="http://resources.bnet.com/topic/digital+video.html"><![CDATA[Digital Video]]></category>
		<category domain="http://resources.bnet.com/topic/internet.html"><![CDATA[Internet]]></category>
		<category domain="http://resources.bnet.com/topic/consumer+electronics.html"><![CDATA[Consumer Electronics]]></category>
		<category domain="http://resources.bnet.com/topic/personal+technology.html"><![CDATA[Personal Technology]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NFLX</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SNE</category>
		<category domain="tickers">NFLX,SNE</category>
	</item>
	<item>
		<title><![CDATA[Biogen-Idec's Tysabri Problems May Be Fault of European Doctors]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005010/biogen-idecs-tysabri-problems-may-be-fault-of-european-doctors/]]></link>
		<description><![CDATA[As mentioned in my last BNET Pharma posting, Biogen Idec's key multiple sclerosis drug Tysabri had been linked to 23 worldwide cases of a potentially deadly brain infection called progressive multifocal leukoencephalopathy, or PML -- with most confirmed cases centered in Europe, in particular Germany. Could there be a link...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 27 Oct 2009 09:47:40 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/germany.html"><![CDATA[Germany]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/microsoft+corp..html"><![CDATA[Microsoft Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[Therapy]]></category>
		<category domain="http://resources.bnet.com/topic/biogen-idec.html"><![CDATA[Biogen-Idec]]></category>
		<category domain="http://resources.bnet.com/topic/tysabri.html"><![CDATA[Tysabri]]></category>
		<category domain="http://resources.bnet.com/topic/pml.html"><![CDATA[PML]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MSFT</category>
		<category domain="tickers">BIIB,MSFT</category>
	</item>
	<item>
		<title><![CDATA[Whatever Tysabri Outcome, Biogen Idec Should Survive]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005002/whatever-tysabri-outcome-biogen-idec-should-survive/]]></link>
		<description><![CDATA[Biogen Idec's key multiple sclerosis drug is in the news again, as the European Medicines Agency EMEA has started a safety review of Tysabri, citing more confirmed cases of a rare -- but potentially fatal -- viral infection of the brain, called progressive multifocal leukoencephalopathy PML, previously linked to the...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 26 Oct 2009 11:21:30 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[Therapy]]></category>
		<category domain="http://resources.bnet.com/topic/tysabri.html"><![CDATA[Tysabri]]></category>
		<category domain="http://resources.bnet.com/topic/progressive+multifocal+leukoencephalopathy.html"><![CDATA[Progressive Multifocal Leukoencephalopathy]]></category>
		<category domain="http://resources.bnet.com/topic/avonex.html"><![CDATA[Avonex]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="tickers">BIIB</category>
	</item>
</channel>
</rss>
